# Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

> **NCT05599256** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 40 (estimated)

## Conditions studied

- Transplant-Related Disorder

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05599256
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-09
- **Primary completion:** 2024-10-07
- **Final completion:** 2025-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599256, "Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05599256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*